The chromosome 16p13.11 heterozygous deletion is associated with a diverse array of neuropsychiatric disorders including intellectual disabilities, autism, schizophrenia, epilepsy and attention-deficit hyperactivity disorder. However the clinical significance of its reciprocal duplication is not clearly defined yet. We evaluated 1645 consecutive pediatric patients with various developmental disorders by high-resolution microarray-based comparative genomic hybridization and identified four deletions and eight duplications within the 16p13.11 region, representing B0.73% (12/1645) of the patients analyzed. Recurrent clinical features in these patients include mental retardation/intellectual disability, autism, seizure, dysmorphic feature or multiple congenital anomalies. Our data expand the spectrum of the clinical findings in patients with these genomic abnormalities and provide further support for the pathogenic involvement of this duplication in patients who carry them.
Approximately 5% of the human genome consists of low copy repeats (LCRs), which are defined as continuous portions of DNA that map to two or more genomic locations with 490% sequence identity and 41 kb in size. 1 LCR-mediated non-allelic homologous recombination is one of the major underlying mechanisms leading to the occurrence of recurrent microdeletion/duplication syndromes. 2 Chromosome 16 is especially rich in intrachromosomal LCRs. Over 10% of the euchromatic region of the short arm of chromosome 16 (16p) is composed of highly complex LCRs. 3 Several distinct genomic disorders on 16p caused by LCR-mediated non-allelic homologous recombination mechanism have been described. [4] [5] [6] [7] [8] [9] One of them is the 16p13.11 microdeletion syndrome characterized by developmental delay/intellectual disabilities (DD/ID) with or without multiple congenital abnormalities. [6] [7] [8] 10, 11 Although 16p13.11 microduplication was initially considered to be a rare benign variant, 6 accumulated evidence indicates that this duplication is enriched in patients with autism, 8 unexplained ID, 10 schizophrenia, 12 epilepsy, 13 and attentiondeficit hyperactivity disorder. 14 Since 2008, we have evaluated 1645 consecutive pediatric patients by microarray-based comparative genomic hybridization (aCGH) technique using the Agilent Human Genome Microarray Kit 244K platform according to the described protocol. 15 Referral justification for the aCGH testing included one or more of the following conditions in these patients: DD, autism, seizure, dysmorphic features or multiple congenital anomalies. The 21 Mb. There were no other genomic abnormalities with clinical relevance in these patients. The genomic imbalances on 16p12.3-p13.11 in these patients were confirmed by quantitative real-time PCR technique targeting to the MYH11 and NDE1 genes within 16p13.11 region based on the procedures published before 16 (data not shown). The quantitative PCR method was also carried out for available parental follow-up studies.
The four patients with the 16p deletion in this study have similar clinical pattern as described before. [6] [7] [8] 10, 11 Recurrent features in the four patients include DD (4/4), epilepsy (3/4) and autism spectrum disorder (2/4). Some isolated findings were also observed, such as, microcephaly, small stature and strabismus. Parental DNA samples were not available to determine the inheritance of the 16p13.11 deletion for patients 9, 10 and 11 whereas the deletion in patient 12 was paternally inherited. Interestingly both parents of the affected child have a history of seizure, DD, and other neurodevelopmental problems. In addition to global DD and epilepsy, one child (patient 9) has craniofacial dysmorphia and multiple congenital anomalies involving heart, kidney, bone, teeth, fingers and toes. We are not sure whether the B1.51 Mb 16p13.11 deletion is the underlying cause of the complex anomalies in this child.
The clinical features in the eight patients with 16p13.11 duplication include DD (4/8), autism spectrum disorder (4/8), attention deficit hyperactivity disorder (2/8), epilepsy (2/8), abnormal MRI of brain (2/8), microcephaly (1/8), macrocephaly (1/8) and congenital heart defect (2/8). Although parental DNA samples for patients 3, 7 and 8 were not available for testing, the duplication in patients 1, 2, 5, and 6 were confirmed to be maternally inherited and the duplication in patient 4 occurred de novo. The mother for patient 1 has cognitive delay and congenital heart defect, but the other three mothers who carried the duplication were reported to be healthy although their complete health information was not available. It is worth mentioning that patient 6 has severe dysmorphism and multiple congenital anomalies involving heart, kidney and bone whereas her mother did not show visible clinical concerns.
Based on other reports and our data it is reasonable to believe that the 16p13.11 duplication with variable breakpoints is a risk factor for a wide spectrum of neurodevelopmental disorders and possibly other clinical features. There are several facts that support the conclusion.
(1) This duplication was independently reported to be associated with a variety of neuropsychiatric problems, such as intellectual disability, autism, schizophrenia, epilepsy and attention-deficit hyperactivity disorder. 8, 10, [12] [13] [14] . Apparently the major clinical features in the eight patients with 16p13.11 duplication in this study are consistent with the clinical findings described in the literatures. (2) The 16p13.11 duplication in patient 4 occurred de novo, providing additional Abbreviations: ADHD, attention deficit hyperactivity disorder; ASD, autism spectrum disorder; CHD, congenital heart defect; DD, developmental delay; del, deletion; dup, duplication; MCA, multiple congenital anomalies; MRI, magnetic resonance imaging.
16p13.11 duplication is a risk factor A Ramalingam et al support about its pathological relevance to autism, attention deficit hyperactivity disorder and anxiety disorder in the patient. (3) The 0.49% (8/1645) detection rate of 16p13.11 duplication in this cohort is significantly higher than that in several recently reported control groups (P40.0001), such as, the 0.09% (31/35 079) in Ingason's report, 12 the 0.08% (1/1156) in Williams' report 14 and 0.00% (0/2493) in Itsara's report. 17 This 0.49% (8/1645) detection rate in our study is also higher than other control groups, although in a less significance statistically, such as the 0.25% (5/2000) in Hannes's report, 6 the 0.21% (6/2792) in Kirov's report, 18 and the 0.22% (7/3181) in a report by the International Schizophrenia Consortium. 19 Non-allelic homologous recombination mediated by LCRs flanking the three intervals within 16p13.11 is likely to be the underlying mechanism leading to the formation of the reciprocal microdeletions/ microduplications as identified in our study and others. 3-9 The B0.8 Mb of interval II with distal breakpoint at 15.40 Mb and proximal breakpoint at 16.20 was shared by all affected individuals carrying 16p13.11 duplication. There are seven annotated genes and transcripts within this region including MPV17L, C16orf45, NDE1, MYH11, C16orf63, ABCC1 and ABCC6. Of them, NDE1 is likely to be the candidate gene responsible for the neurological and behavioral phenotypes observed in patients with the deletion and duplication of this region. This gene encodes a member of the nuclear distribution E (NudE) family of proteins having an essential role in microtubule organization, mitosis and neuronal migration. 20 The Nde1-null mice showed small-brain phenotype with the cerebral cortex being affected the most. 21 The interaction of Nde1 with Lis1 seems to be essential for the development of mouse central nervous system. 22 No mutation in NDE1 was identified in the retained homologous allele in patients carrying 16p13.11 heterozygous deletions, suggesting that haploinsufficiency of this gene could be the underlying genetic mechanism leading to the abnormal clinical features in these patients who carry the deletion. 6 However, the clinical significance of the three copies of NDE1 gene remains unknown at this point.
In summary, we identified 12 patients carrying genomic imbalances within 16p12.3p13.11 region, representing B0.73% of the patients analyzed. Our data expanded the spectrum of the clinical findings in patients with these genomic abnormalities. The 0.49% (8/1645) detection rate of 16p13.11 duplication in this cohort is significantly higher than that in several control groups, providing further support for the pathogenic involvement of this duplication. 16p13.11 duplication is a risk factor
